Indobufen: An updated review of its use in the management of atherothrombosis

Drugs and Aging

Volumn 18, Issue 5, 2001, Pages 369-388

  Bhana, Nila ^a   McClellan, Karen J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; INDOBUFEN; PENTOXIFYLLINE; WARFARIN;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; INTERMITTENT CLAUDICATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS;

EID: 0034997544     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118050-00007     Document Type: Review

References (77)

1. 1. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prosta-glandin endoperoxides. Proc Natl Acad Sci U S A 1975; 72: 2994-8
2. 2. Wiseman LR, Fitton A, Buckley MM. Indobufen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease. Drugs 1992 Sep: 44: 445-64
3. 3. Patrignani P, Volpi D, Ferrario R, et al. Effects of racemic, S-and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. Eur J Pharmacol 1990; 191: 83-8
4. 4. De Caterina R, Sicari R, Yan A, et al. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. Thromb Haemost 1992; 67 (2): 258-63
5. 5. Strolin Benedetti M, Frigerio E. Tamassia V, et al. The dispositional enantioselectivity of indobufen in man. Biochem Pharmacol 1992 May 8; 43 (9): 2032-4
6. 6. Pinto S, Abbate R, Favilla S. et al. Ex vivo and in vitro study of the effects of indobufen on endogenous and exogenous ara-chidonic acid metabolism by platelets. Curr Ther Res 1987; 42 (2): 243-52
7. 2 production. Haemostasis 1987; 17: 293-300
8. 8. Davi G, Francavilla G, Mattina A, et al. Indobufen treatment in agina pectoris: effects on platelet function and the thromboxane synthesis. Curr Ther Res 1988; 43 (6): 1031-7
9. 9. Mannucci L, Maderna P, Colli S, et al. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res 1987; 48; 417-26
10. 2 production in patients with myocardial infarction. Eur J Clin Pharmacol 1990; 39: 99-100
11. 11. Pogliani E, Corvi G, Mandelli V, et al. Preliminary human pharmacology studies on the inhibition of platelet aggregation by indobufen (K 3920). Haematologica 1981; 66 (2); 159-70
12. 12. Tamassia V, Corvi G, Fuccella LM, et al. Indobufen (K 3920), a new inhibitor of platelet aggregation; effect of food on bio-availability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man. Eur J Clin Pharmacol 1979; 15 (5): 329-33
13. 13. Crow MJ, Salter DR, Donaldson DR, et al. Inhibition of platelet function with indobufen: correlation with plasma drug level. Thromb Res 1985; 38: 303-6
14. 14. Visonà A, Davanzo S, Bruno R, et al. Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP). J Int Med Res 1983; 11: 10-4
15. 15. Vinazzer H, Fuccella LM. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggreeetion. J Clin Pharmacol 1980; 20: 316-25
16. 16. Carrieri P, Orefice G. Study of platelet function in vitro and in vivo in patients with transient cerebral ischaemia: effects of short-term treatment with a new platelet antiaggregant drug, indobufen. Curr Ther Res 1984; 36 (4): 681-6
17. 17. Orefice G, Carrieri P, Indaco A, et al. A comparative study between indobufen and acetylsalicylic acid on β-thromboglobulin: platelet factor 4 and platelet aggregation in patients with transient ischemic attacks. Acta Neurol Scand 1984; 6: 97-102
18. 18. Pogliani EM, Fantasia R. Savino R, et al. Platelet release reaction and prostaglandin pathway activation in angina patients during exercise: effect of indobufen. J Int Med Res 1983; 11: 6-9
19. 19. Nenci GG, Berrettini M, Iadevaia V, et al. Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920): a randomized, double-blind crossover study on platelet, coagualtion and fibrinolysis function tests, Pharmatherapeutica 1982; 3 (3): 188-94
20. 20. Nubile G. Lavezzari M, Stragliotto E. Indobufen reduces the expression of the platelet glycoprotein IIb-IIIa complex [abstract]. 3rd International Symposium Multiple Risk Factors in Cardiovascular Disease Vascular and Organ Protection; 1994; Florence, 37
21. 21. Ciavarella N, Corvi G, Coviello M, et al. The effect of indobufen (K 3920) on platelet aggregation, platelet factors 3, 4, and some coagulation parameters in patients with venous thrombosis. Curr Ther Res 1981; 29 (3): 503-9
22. 22. Pogliani EM, Fowst C. Bregani R, et al. Bleeding time and antiplatelet agents in normal volunteers. Int J Clin Lab Res 1992; 22 (1): 58-61
23. 23. Chello M, Mastroroberto P. Celi V, et al. Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease. J Cardiovasc Pharmacol 1996 Mar; 27: 417-23
24. 24. Grasselli S, Guerciolini R, Iadevaia V, et al. In vitro and ex vivo effects of indobufen on red blood cell deformability. Eur J Clin Pharmacol 1987; 32: 207-10
25. 25. DiMinno G. Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo: potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983; 225 (1): 57-60
26. 26. Carrieri P, Donzelli R, Orefice G, et al. Antithrombotic effect of indobufen in an experimental model of arterio-arterial microanastomosis in the rat. Thromb Res 1987; 45: 195-9
27. 27. Lane IF. Irwin JTC, Jennings SA. Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in prosthetic vascular grafts. Br J Surg 1986; 73: 563-5
28. 28. Signorini GP, Salmistraro G. Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology 1988; 39: 742-5
29. 29. Beclaro G. Vasospasm in intermittent claudication: effects of indobufen defibrotide, and combination treatment. Curr Ther Res 1990; 48 (4): 667-74
30. 30. Zacharieva S. Orbetzova D, Tcharaktchiev D, et al. Effects of short-term treatment with the thromboxane synthesis blocker indobufen on pressor and depressor humoral factors in healthy humans. Methods Find Exp Clin Pharmacol 1995; 17 (9): 615-9
31. 31. De Caterina R, Giannessi D, Bernini W, et al. A prostacyclinsparing effect of indobufen vs. aspirin. Thromb Haemost 1996; 75 (3): 510-4
32. 32. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997 Aug 19; 96: 1109-16
33. 33. Simic DV, Avramovic D. Matic D. et al. Indobufen treatment in angina pectoris: effects on platelet aggregation [abstract]. 6th International Congress on Cardiovascular Pharmacotherapy: 1996 Feb 26: Sydney, A43
34. 34. Szczepanska-Szerej A. Wojczal J. Stelmasiak Z. Anti-aggregating effect of indobufen in acute ischemic stroke [abstract]. Eur J Neurol 1998 Sep; 5 Suppl. 3: S109
35. 35. Wojczal J. Szczepanska-Szerej A, Stelmasiak Z. Pentoxyfilline (PTX) and indobufen (IB) reduce platelet activation in the acute phase of ischemic stroke (IS) [abstract no. MTS135]. Eur J Neurol 1998 Sep; 5 Suppl. 3: S108
36. 36. Savazzi GM, Castiglioni A, Cavatorta A. Effect of renal insufficiency on the pharmacokinetics of indobufen. Curr Ther Res 1984; 36 (1): 119-25
37. 37. Savazzi GM, Castiglioni A, Cavatorta A, et al. Effect of age on the pharmacokinetics of indobufen. Int J Clin Pharmacol Ther Toxicol 1986; 24 (5): 265-9
38. 38. Fuccella LM, Corvi G, Moro E, et al. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Eur J Clin Pharmacol 1979; 15 (5): 323-7
39. 39. Glowka FK. Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man. Chirality 2000 Jan; 12: 38-42
40. 40. Elvander-Ståhl E, Melander A, Wåhlin-Boll E. Indobufen interacts with the sulphonylurea, glipizide, but not with the β-adrenergic receptor antagonists, propranolol and atenolol. Br J Clin Pharmacol 1984; 18: 773-8
41. 41. Antiplate let Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
42. 42. Battaglia A. Stragliotto E. Heiman F, et al. Indobufen in the secondary prevention of cerebral ischemic attack (TIA): a prospective, randomized, controlled study [abstract no. 2896]. Thromb Haemost 1993 Jun 30; 69: 1349
43. 43. Bergamasco B, Benna P, Carolei A, et al. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Funct Neurol 1997 Jan-Feb; 12: 33-43
44. 44. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62
45. 45. Li-Saw-Hee FL. Lip GYH. Atrial fibrillation, thromboembolism and antithrombotíc therapy. Int J Clin Practice 1999; 53 (2): 110-7
46. 46. Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease: a randomized, placebo-controlled, double-blind study. Circulation 1993 Jan; 87: 162-4
47. 47. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997 May; 28: 1015-21
48. 48. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy≡II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68
49. 49. The SINBA Group. Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coron Artery Dis 1991 ; 2: 897-906
50. 50. Rajah SM, Nair U, Rees M, et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994 Apr; 107: 1146-53
51. 51. D'Addato M, Curti T, Bertini D, et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. Int Angiol 1992 Apr-Jun; 11: 106-12
52. 52. Belcaro G, De Simone P. Long-term evaluation of indobufen in peripheral vascular disease. Angiology 1991; 42: 8-14
53. 53. Panchenko E, Eshkeeva A, Dobrovolsky A. et al. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment. Angiology 1997 Mar; 48 (3): 247-54
54. 54. Tonnesen KH, Albuquerque P, Baitsch G, et al. Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication, Int Angiol 1993 Dec: 12: 371-7
55. 55. Lavezzari M, Milanesi G, Sacchetti G, et al. Indobufen: results of a postmarketing surveillance study on 5,642 cases. Curr Ther Res 1989; 46 (1): 19-27
56. 56. Carlo Erba. Ibustrin (indobufen) prescribing information. Pharmacia and Upjohn, Milan, Italy, 2000
57. 57. Wilson JM, Ferguson III JJ. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol 1999; 22: 687-98
58. 58. Patrona C. Coller B, Dalen JE. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S-88S
59. 59. Bath PMW, Lees KR. ABC of arterial and venous disease: acute stroke. BMJ 2000; 320: 920-3
60. 60. Lees KR, Bath PMW. Naylor AR, ABC of arterial and venous disease: secondary prevention of transient ischaemic attack and stroke. BMJ 2000; 320: 991-4
61. 61. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 Jun 3; 1 (8649): 1215-20
62. 62. Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 24: 501-7
63. 63. Roche Pharmaceuticals. TICLID (ticlopidine hydrochloride) prescribing information. New Jersey, 2000
64. 64. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
65. 65. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7
66. 66. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (8): 983-8
67. 67. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-57
68. 68. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119 Suppl. 1: 194S-206S
69. 69. Lip GYH. Thromboprophylaxis for atrial fibrillation. Lancet 1999; 353 (9146): 4-6
70. 70. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000; 15 (1): 56-67
71. 71. Hardman SMC, Cowie MR. Anticoagulation in heart disease. BMJ 1999 Jan 23; 318: 238-44
72. 72. Taylor FC, Cohen H. Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321-6
73. 73. Cattaneo M. Prevention of thromboembolism in atrial fibrillation of non-valvular etiology. Ann Ital Med Int 1996 Oct; 11 Suppl. 2: 15S-7S
74. 74. Campos EE, Cinderella JA, Farhi ER. Long-term angiographic follow-up of normal and minimally diseased saphenous vein grafts. J Am Coll Cardiol 1993; 21 (5): 1175-80
75. 75. Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2001; 119 Suppl.: 278S-82S
76. 76. Moher D, Pham B, Ausejo M, et al. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000 May; 59: 1057-70
77. 77. Girolami B, Bernardi E. Prins MH, et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999 May; 81 : 715-22